midazolamMorphineoctreotidedinoprostoneClonidinedopaminenoradrenalinefurosemideglucagonatracurium+1 more
…isible particles, and degradation products.Conclusion Morphine, midazolam, noradrenaline, dopamine, and clonidine are strong candidates f…
Browse by entity family
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Funders
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentions29,499matching articles
244,054matching entity mentions
30popular entities listed
0%of mentions human-reviewed
Popular entities in these results
Choose an entity to see the articles in which it was identified.
EMBASE784PUBMED717COVID-19645Cancer605SLE570Diabetes552NHS522WEB OF SCIENCE499Hypertension418SCOPUS417HIV406Systemic Lupus Erythematosus390Heart Failure364Asthma349Stroke336COPD331WHO330Colorectal Cancer327Cardiovascular Disease317Type 2 Diabetes316Chronic Obstructive Pulmonary Disease313Joanna Briggs Institute306MEDLINE306Atrial Fibrillation283Cochrane Library275Breast Cancer271Hepatocellular Carcinoma253SSc251Inflammatory Bowel Disease250Obesity246
Matching articles
29,499 articles · page 35 of 2459Risankizumabulcerative colitispsoriasisCrohn’s diseasepsoriatic arthritisPsAPsOUC
… the median age was 50 (16-84) years, 53.1% of whom were women. Risankizumab prescriptions were for: PsO (58.4%), CD (30.1%), PsA (10.6%), a…
chronic migraineatogepantCMBTX-ATOATOm
…elevance Results suggest that the effectiveness of atogepant in chronic migraine, in terms of reducing monthly migraine days, is comparable betw…
migraineatogepantrimegepant
…clusion and Relevance Oral CGRP antagonists effectively reduced migraine frequency and improved quality of life in real-world settings. …
type 2 diabetesmyocardial infarctiondiabeteskidney diseaseGLP-1RAssulphonylureaGLP-1 receptor agonistsstroke
…mised controlled trials. Randomising GLP-1RA de-prescription in type 2 diabetes would pose ethical concerns, given the proven benefits of GLP-1…
anifrolumabhydroxychloroquinesystemic lupus erythematosusprednisoloneshinglesgabapentinmethotrexate
… Due to therapeutic failure with rituximab, she was switched to anifrolumab. Twelve days after the first infusion, she developed a painful …
isoniazid-basedrifamycin-basedWHOHIVTBTPTtuberculosis
…als compared with other facility types. Clinics reported use of isoniazid-based (160 clinics, 93%) and shorter rifamycin-based (129 clinics, 75…
chronic kidney diseasetype 2 diabetesSGLT2iGLP-1 RACKDT2Dsodium-glucose cotransporter 2 inhibitorsglucagon-like peptide-1 receptor agonists
…ly evolving therapeutic landscape for type 2 diabetes (T2D) and chronic kidney disease (CKD), this study aimed to characterise the clinical profiles a…
tuvusertibN-803National Cancer InstituteAtaxia telangiectasia
…l in athymic nude mice was utilized to evaluate the efficacy of tuvusertib and N-803 combination therapy in vivo. Tuvusertib and avelumab …
asthmamonoclonal antibody therapyCOPD
…rticularly elevated eosinophil count,when making a diagnosis of asthma. We investigated the pattern of eosinophilic inflammation in pa…